United Therapeutics Corpo... (UTHR)
NASDAQ: UTHR
· Real-Time Price · USD
453.07
9.63 (2.17%)
At close: Oct 03, 2025, 3:59 PM
452.80
-0.06%
After-hours: Oct 03, 2025, 06:54 PM EDT
2.17% (1D)
| Bid | 431 |
| Market Cap | 20.49B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | 1.24B |
| EPS (ttm) | 25.63 |
| PE Ratio (ttm) | 17.68 |
| Forward PE | 15.14 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 459.92 |
| Volume | 778,637 |
| Avg. Volume (20D) | 773,147 |
| Open | 443.63 |
| Previous Close | 443.44 |
| Day's Range | 443.63 - 455.12 |
| 52-Week Range | 266.98 - 455.13 |
| Beta | 0.66 |
| Ex-Dividend Date | n/a |
About UTHR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol UTHR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for UTHR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsUnited Therapeutics Corporation is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.27%
United Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+32.83%
United Therapeutics shares are trading higher after the company announced that its TETON-2 study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity relative to placebo.
1 month ago · proactiveinvestors.com
United Therapeutics shares jump on positive lung disease study resultsUnited Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TET...